Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

London pre-open: Stocks seen higher; retail sales disappoint

(Sharecast News) - London stocks were set to rise at the open on Friday following heavy losses a day earlier, as investors mulled disappointing retail sales data. The FTSE 100 was called to open up around 15 points.

Figures released earlier by the Office for National Statistics showed that retail sales unexpectedly fell in October as wet weather and the cost-of-living crisis took their toll.

Retail sales fell 0.3% on the month following a revised 1.1% decline in September, missing expectations for a 0.3% increase.

Heather Bovill, deputy director for surveys and economic indicators at the ONS, said: "Retail sales fell again in October to their lowest level since February 2021 when widespread lockdown restrictions were in place.

"After rebounding in September, fuel sales dipped with increasing prices discouraging customers, while food sales also dropped as consumers prioritised essential goods.

"It was another poor month for household goods and clothes stores with these retailers reporting that cost-of-living pressures, reduced footfall and poor weather hit them hard.

"However, it was a better month for online retailers, the only main sector to report growth in October."

In corporate news, AstraZeneca's Truqap, in combination with Faslodex, has received US FDA approval for treating adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer with specific biomarker alterations and who previously progressed on endocrine-based therapy.

The approval is based on positive results from a phase three trial, showing a 50% reduction in the risk of disease progression or death when compared to Faslodex alone in patients with relevant biomarker alterations.

AstraZeneca said the approval addressed a significant need in breast cancer treatment, as the biomarker alterations affected up to 50% of advanced HR-positive breast cancer patients who develop resistance to first-line therapies.

Aberdeen-based transport company FirstGroup signed a deal with Hitachi that will see it buy up to 1,000 electric bus batteries as it works towards is decarbonisation targets.

The partnership will see the creation of a new 50:50 joint venture, NextGen Asset Co, to buy the batteries valued at £100m, leased over an eight-year period. In exchange, Hitachi will provide battery and charging management services for 1,000 buses powered by the new batteries.

Share this article

Related Sharecast Articles

London pre-open: Stocks seen up ahead of US CPI
(Sharecast News) - London stocks were set to rise at the open on Wednesday following a positive session on Wall street, as investors eyed the latest US inflation reading.
London close: Stocks manage gains as unemployment rises
(Sharecast News) - London stocks closed higher on Tuesday, as investors analysed the latest UK jobs data and remarks from Bank of England chief economist Huw Pill.
London midday: FTSE touch firmer after jobs data, Pill comments
(Sharecast News) - London stocks were still just a touch firmer by midday on Tuesday as investors mulled the latest jobs data and comments from Bank of England chief economist Huw Pill.
London open: Stocks nudge up as investors mull jobs data
(Sharecast News) - London stocks were just a touch higher in early trade on Tuesday as investors mulled conflicting UK jobs data.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.